



Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The Liver Meeting® 2021

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12 - 15, 2021.

All posters presented will be available on the Aligos website at [Scientific Presentations & Conferences](#) following the conclusion of the conference.

Chronic Hepatitis B

S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPST™)

Title: S-antigen Transport-inhibiting Oligonucleotide Polymers, (STOPST™) Sequester Cellular Proteins to Reduce Hepatitis B Virus S-Antigen Expression and Increase Its Proteasomal Degradation

Publication Number: 845

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: C. Cheng Kao

Capsid Assembly Modulator (CAM)

Title: Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)

Publication Number: 843

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: Ed Gane

Antisense Oligonucleotide (ASO)

Title: Best-in-Class Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Significantly Increase *In Vivo* Efficacy and Reduce Hepatotoxicity in Mice

Publication Number: 820

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: Dinah Misner

Title: ALG-020572, a GalNAc-Conjugated Antisense Oligonucleotide, Demonstrates *In Vivo* Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B

Publication Number: 819

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: Kusum Gupta

siRNA

Title: Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model

Publication Number: 831

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: Jin Hong

Combinations

Title: Triple Combination of Anti-Hepatitis B Virus Drugs Demonstrates Synergistic Activity *In Vitro*

Publication Number: 852

Session Title: Hepatitis B: Therapeutics: New Agents

Presenter: Hua Tan

NASH

Title: Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics

Publication Number: 1932

Session Title: NAFLD and NASH: Therapeutics

Presenter: Kusum Gupta

Title: Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH

Publication Number: 1907

Session Title: NAFLD and NASH: Therapeutics

Presenter: Xuan Luong

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos's strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements". Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com